Clinical Trial Update: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluating non-myeloablative allogeneic HSCT from HLA-matched related or unrelated donors in low-grade B-cell malignancies was terminated; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Multiple Myeloma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Multiple Myeloma, CLL / SLL | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2017-05-04